Robertson Stephens Wealth Management’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.5K Hold
12,000
﹤0.01% 644
2026
Q1
$12.7K Sell
12,000
-14,000
-54% -$1.05K ﹤0.01% 614
2025
Q4
$40.6K Buy
+26,000
New +$2.69K ﹤0.01% 636

Robertson Stephens Wealth Management's ESLAW Position: Q2 2026 in Review

Robertson Stephens Wealth Management held its Estrella Immunopharma Warrant (ESLAW) position steady in Q2 2026 at 12,000 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #644.

Robertson Stephens Wealth Management first reported a position in ESLAW in Q4 2025 and has held it in 3 quarters since. The position peaked at $40.6K in Q4 2025. 1 fund tracked by Wall St. Rank holds ESLAW as of Q2 2026.

  • Robertson Stephens Wealth Management held 12,000 shares of Estrella Immunopharma Warrant worth $12.5K as of Q2 2026.
  • Robertson Stephens Wealth Management left its Estrella Immunopharma Warrant share count unchanged in Q2 2026.
  • Estrella Immunopharma Warrant made up ﹤0.01% of Robertson Stephens Wealth Management's portfolio in Q2 2026, its #644 holding.
  • Robertson Stephens Wealth Management first reported a position in Estrella Immunopharma Warrant in Q4 2025 and has held it in 3 quarters since.
  • Robertson Stephens Wealth Management's Estrella Immunopharma Warrant position peaked at $40.6K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q2 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.